GeneSys Biologics, an Indian biotechnology company based in Hyderabad, launched its integrated drug development facility in Genome Valley, Shameerpet (India).
The new facility will manufacture insulin biosimilars across the value chain from research and development to commercial manufacturing. The new production facility will contribute towards the company’s global clinical programme for multiple products. It will also cater to the future commercial requirements of India and other emerging markets.
The facility houses a research and development centre, quality analysis and quality control labs. The unit is compliant with relevant good manufacturing practices (GMP) regulations.
GeneSys Biologics focuses on biosimilar molecules and other fermentation based products.